Clinical trial · Interventional
Cryobiopsy for Suspected Malignant Peripheral Lymphadenopathy
NCT06120829CI-TRIAL-00071094COLD SNAPunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cryobiopsy of peripheral lymph nodes with suspected malignant potential with comparison to standard core needle biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cryobiopsy of Peripheral Lymph Nodes | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Core Needle Biopsy | Procedure | — | UNRESOLVED |
| Cryobiopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Control Arm
- description
- FNA followed by Core Needle biopsy
- interventionNames
- Procedure: Core Needle Biopsy
- type
- EXPERIMENTAL
- label
- Experimental Arm
- description
- FNA followed by cryobiopsy through a introducer sheath
- interventionNames
- Procedure: Cryobiopsy
- Device: Cryobiopsy
Primary outcomes (1)
- measure
- Yield by strict criteria
- timeFrame
- 7 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-89 * Suspected or confirmed malignancy with suspected involvement of peripheral lymph nodes based on CT, PET-CT or ultrasound imaging with a clinical need for additional tissue or staging by tissue sampling Exclusion Criteria: * Age \<18 or \>89 * Patient preference * Severe allergy to lidocaine precluding use * Severe allergy to chlorhexidine precluding use * Overlying Infection * Active anticoagulation or anti-platelet therapy, with the exception of aspirin mono-therapy, that cannot be safely held as determined by the performing or prescribing physician. * Major organs, vasculature or tissue that would preclude the safety of the procedure as determined by the performing physician. * Inability to reach the lymph node through a core needle introducer sheath as determined by the performing physician.
References
Publications (0)
Data not yet available
No reference posted for this study.